Abstract
Probiotics are a potential treatment agent for IBD. In this study, the effects of probiotics on intestinal immune responses and gut microbiota in colitis were investigated. The result showed that L. plantarum AR113 and L. casei AR342 were 2–3 times more effective than other strains to alleviate epithelial damage indicators, improve colon length (+10–30%) and maintain the integrity of the epithelial barrier, as compared to DSS-treatment mice. The supplementation downregulated expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and upregulated that of the colonic anti-inflammatory cytokine (IL-10). The results strongly suggested that anti-inflammatory effect of probiotics is associated with the increase in HO-1 expression and the decrease in TLR4/MyD88/NF-κB pathway expression in mouse colonic tissues. Further, Microbiota analysis and the correlation of microbiota with colitis parameters revealed that the dysbiosis of gut microbiota induced by DSS treatment could be mitigated to a certain extent by supplementation with L. plantarum AR113.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
